+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.

Age: 18Years - 100YearsAll Genders
287 locations
S

Actively Recruiting

Researchers are evaluating the addition of Tersolisib LY4064809STX-478 to other anti-cancer drugs as a first treatment for adults with advanced hormone receptor-positive HR and human epidermal growth factor receptor 2-negative HER2- breast cancer that has a PIK3CA genetic mutation. The study aims to assess the effectiveness and safety of this combination in people whose cancer cannot be cured by surgery alone. Participants may continue in the study as long as the treatment is helping and side effects are manageable. Participants will be randomly assigned to one of three groups two different doses of Tersolisib combined with a CDK46 inhibitor and endocrine therapy ET, or a placebo combined with the same drugs. The CDK46 inhibitor and ET are given orally or intramuscularly depending on the drug chosen by the investigator. Treatments are administered orally or by injection as appropriate. The study includes a phase 2 dose optimization portion and a phase 3 randomized, double-blind, placebo-controlled portion. During the study, participants will undergo regular assessments including scans and tests to measure tumor response and progression. Researchers will monitor overall response rate, progression-free survival, and other health outcomes for up to 5 to 7 years. Safety and drug levels in the blood will also be tracked. Participants quality of life and physical function will be evaluated using questionnaires. The total time in the study depends on individual treatment response and side effects.

Age: 18Years +All GendersPhase 3
364 locations
P

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and quality of life for combining Abemaciclib with either an Aromatase Inhibitor or Fulvestrant in women with metastatic hormone receptor-positive, HER2-negative breast cancer. This Phase IV trial focuses on both pre- and postmenopausal patients receiving first-line treatment. A digital health app called CANKADO will be used to track side effects and patient-reported outcomes daily, alongside standard documentation. The study also aims to explore biomarkers to better understand treatment responses and resistance. Participants will receive either Abemaciclib combined with an Aromatase Inhibitor Anastrozole, Letrozole, or Exemestane taken orally twice daily plus daily Aromatase Inhibitor tablets every 24 hours in 28-day cycles, or Abemaciclib with Fulvestrant which is given as an injection on specific days within 28-day cycles. The two treatment groups are experimental and non-randomized, with no masking. The trial includes monitoring for side effects and quality of life throughout treatment. During the study, participants will regularly report side effects and global health status using questionnaires at multiple time points up to 24 months, including specialized breast cancer quality of life modules. Researchers will assess progression-free survival up to 48 months, as well as adverse events, hospitalizations, clinical benefit rate, overall survival, and tumor response. The use of the CANKADO app for side effect reporting is strongly recommended but not mandatory. Participants will be followed for safety and outcomes throughout the trial duration.

Age: 18Years +FEMALEPhase 4
54 locations
P

Actively Recruiting

Researchers are investigating the effects of stopping CDK46 inhibitors in women with metastatic hormone receptor HR positive, HER2 negative breast cancer who have maintained disease control after long-term treatment. This phase II trial aims to evaluate whether disease stability continues when CDK46 inhibitors are discontinued after at least 12 months of combined treatment with endocrine therapy. The study is open-label, randomized, and conducted at multiple centers. Participants are randomly assigned to one of two groups one group continues both CDK46 inhibitor treatment such as Palbociclib or Abemaciclib and endocrine therapy, while the other group discontinues the CDK46 inhibitor but continues endocrine therapy alone. The study monitors disease progression and treatment effects over time, with a focus on how long patients remain free from disease worsening after stopping the CDK46 inhibitor. During the study, participants will be regularly assessed for disease progression, safety, and quality of life using questionnaires and clinical evaluations. Researchers will measure progression-free survival at 12 months and up to 54 months, time to treatment failure, time to first chemotherapy use, and monitor adverse events. The total participation duration may extend beyond four years, with ongoing evaluations to understand long-term outcomes and safety after stopping the CDK46 inhibitor.

Age: 18Years +FEMALEPhase 2
13 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety of two drugs, Deucravacitinib and Ustekinumab, in adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic treatments. This study is designed to compare these treatments over an extended period, focusing on cardiovascular health and other safety outcomes. The study is sponsored by Bristol-Myers Squibb and is a Phase 3b4 randomized, open-label trial. Participants are randomly assigned to receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study spans up to 5 years, during which participants will be monitored closely for cardiovascular events and other safety outcomes. Treatment adherence and effects will be regularly assessed throughout this long-term safety study. During the study, participants will undergo various evaluations including monitoring for major cardiovascular events such as heart attacks and strokes, other cardiovascular complications, and laboratory assessments including liver function and lipid panels. Researchers will also track serious adverse events and overall mortality up to 60 days after the last dose. This comprehensive monitoring ensures participant safety and gathers essential data on the long-term effects of the treatments over the studys duration, which lasts until January 2031.

Age: 40Years +All GendersPhase 3
411 locations
S

Actively Recruiting

Patients with atrial fibrillation who undergo percutaneous coronary intervention PCI with stent implantation need different antithrombotic drugs to prevent stroke and heart complications. Current standard treatment includes three antithrombotic drugs for 1 week to 1 month, then two drugs for 6 to 12 months, followed by long-term treatment with one anticoagulant. Researchers are studying whether a single drug approach can reduce bleeding while still protecting against clotting events in a large trial of 3,010 patients. This study compares two treatment plans. One group takes a P2Y12 inhibitor alone for 1 month after stent placement, then switches to a direct-acting oral anticoagulant DOAC alone for 11 months. The other group follows standard care triple therapy aspirin, P2Y12 inhibitor, DOAC for up to 1 month, dual therapy P2Y12 inhibitor and DOAC for 6 to 12 months, and then DOAC alone. The study is randomized, open-label, and conducted across multiple sites internationally. Participants are monitored over 12 months with assessments of major cardiac or cerebral events like death, heart attack, stroke, and systemic embolism, as well as bleeding complications. Researchers will track hospitalizations, revascularizations, and detailed bleeding events using established criteria. After the study, patients receive routine care. The trial aims to find a safer, effective antithrombotic approach for atrial fibrillation patients after stent implantation.

Age: 18Years +All GendersPhase 4
15 locations
S

Actively Recruiting

Researchers are evaluating the safety and performance of RefluxStop2, a device used in the treatment of Gastroesophageal Reflux Disease GERD. This post-market registry study focuses on patients receiving standard care procedures to better understand how RefluxStop performs in general hospital practice. The study is sponsored by Implantica CE Reflux Ltd. and tracks outcomes over several years. Participants will be treated with either the RefluxStop device implantation using a standard surgical technique or undergo the standard of care Nissen fundoplication surgery for GERD. Both interventions are observed under typical clinical conditions. The study includes follow-up periods at 3, 6 months, and annually up to 5 years to monitor both safety and performance. During the study, participants will have regular assessments including pH monitoring and hernia evaluations. Researchers will track the position of the RefluxStop device and measure reflux symptoms using specific safety and performance endpoints at 3 and 6 months, and then yearly for up to 5 years. The total duration of participation varies, with key outcome measurements focused on the first 6 months and long-term follow-up ongoing.

Age: 18Years +All Genders
6 locations
F

Actively Recruiting

Researchers are conducting a multicenter observational study to follow up on patients with severe tricuspid regurgitation who have been treated with the TricValve4 Transcatheter Bicaval Valves System. This study aims to monitor the long-term outcomes and health status of these patients after receiving this specific valve treatment. It includes patients who have undergone this procedure and focuses on assessing their heart function and related complications over time. Participants in the study have already been treated with the TricValve device in both the Inferior Vena Cava and Superior Vena Cava. The study involves a follow-up period lasting up to five years, with scheduled clinical visits at discharge, 1 month, 6 months, 1 year, and annually thereafter up to 5 years. During these visits, routine tests such as blood counts, kidney function tests, electrocardiograms, and echocardiograms are performed to evaluate the valves function and the hearts hemodynamic status. Throughout the follow-up, researchers will track important health outcomes, including hospital readmissions for heart failure, mortality rates, adverse events, changes in heart function and valve performance, and patient functional status using the New York Heart Association NYHA classification. The study will also assess biomarkers related to heart function and medication adjustments. These comprehensive evaluations help researchers understand the safety and durability of the TricValve system over time.

Age: 18Years +All Genders
28 locations
R

Actively Recruiting

Plaque psoriasis is a chronic inflammatory skin condition that causes thick, red, and scaly patches. This research evaluates how treatment with risankizumab affects the quality of life in adults with moderate to severe plaque psoriasis in real-world clinical settings. About 700 participants prescribed risankizumab by their doctors according to local guidelines will be involved in this study. Participants will receive risankizumab as directed by their physicians based on routine care and local labeling. There are no additional treatments or study drugs provided beyond what is normally prescribed. The study is observational and follows participants for up to 2.5 years while they continue their usual treatment. During the study, participants will attend regular visits at hospitals or clinics as part of their standard care. Researchers will assess outcomes such as the proportion of participants achieving a Dermatology Life Quality Index DLQI score of 0 or 1 at 12 months. The study aims to understand the impact of risankizumab on quality of life with minimal extra burden to participants.

Age: 18Years +All Genders
84 locations
O

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a subcutaneous treatment using one cycle of cladribine for patients with hairy cell leukemia who need treatment. This study focuses on patients who are either untreated or have been previously treated only with alpha-interferon. The goal is to determine the rate of complete remission and to assess whether a second cycle of treatment benefits those with a non-optimal response, defined as detectable residual disease or partial remission four months after the initial treatment. Participants receive cladribine at a dose of 0.14 mgkg body weight administered subcutaneously as a bolus injection once daily for five consecutive days. After four months, remission status is evaluated. Patients showing non-optimal response may be considered for a second treatment cycle. This phase 23 trial is designed to optimize therapy for hairy cell leukemia by closely monitoring treatment response and toxicity. During the study, participants undergo evaluations including disease status assessment through bone marrow and blood tests, with a focus on remission rates four months post-treatment. Researchers track complete remission rates and monitor for residual disease. Safety is also monitored by assessing potential toxicities. Participants general health status and other laboratory tests are reviewed to ensure eligibility and ongoing suitability for treatment throughout the study period, which spans several months with follow-up assessments.

Age: 18Years - 90YearsAll GendersPhase 2Phase 3
76 locations